Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for LA or Metastatic Merkel cell carcinoma (MCC)

 Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for LA or Metastatic Merkel cell carcinoma (MCC)

Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for LA or Metastatic Merkel cell carcinoma (MCC)

Shots:

  • The approval is based on P-II CITN-09/KEYNOTE-017 study assessing Keytruda in 50 patients with recurrent LA or mMCC who had not received prior systemic therapy
  • P-II CITN-09/KEYNOTE-017 study results: ORR 56%; CR 24%; PR 32%; DOR @6 mos./ 12 mos. (96%, 54%); median duration of exposure 6.6 mos.
  • Keytruda (pembrolizumab) 100mg IV is a mAb, used as an anti-D-L1 therapy that blocks interaction between PD-1 and its ligands i.e PD-L1 & PD- L2, further activating T lymphocytes

Click here to read full press release/ article | Ref: Merck & Co | Image: The Street

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post